Recombinant Mouse Siglec-2 (C-6His)

Description

EnkiLife provides the Recombinant Mouse Siglec-2 (C-6His) protein,aslo know as B-cell receptor CD22,BL-CAM,B-lymphocyte cell adhesion molecule,CD22 antigenMGC130020,CD22 molecule,CD22,sialic acid binding Ig-like lectin 2,Siglec-2,SIGLEC2FLJ22814,T-cell surface antigen Leu-14, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Mouse B-cell Receptor CD22 is produced by our Mammalian expression system and the target gene encoding Ser22-Arg702 is expressed with a 6His tag at the C-terminus.Accession:AAA02562.1. Expression Host:Human Cells.Species:Mouse.Predicted Molecular Mass:77.3 KDa. Background:Siglecs (sialic acid binding Ig-like lectins) are I-type (Ig-type) lectins belonging to the Ig superfamily. They are characterized by an N-terminal Ig-like V-type domain which mediates sialic acid binding, followed by varying numbers of Ig-like C2-type domains. Human Siglec-2, also known as B-cell antigen CD22 or B-lymphocyte cell adhesion molecule (BL-CAM), is a B-cell restricted glycoprotein that is expressed in the cytoplasm of progenitor B and pre-B cells and on the surface of mature B cells. Two distinct human Siglec-2/CD22 cDNAs that arise from differential RNA processing of the same gene have been isolated. Siglec-2/CD22 is an adhesion molecule that preferentially binds alpha 2,6- linked sialic acid on the same (cis) or adjacent (trans) cells. Interaction of CD22 with trans ligands on opposing cells was found to be favored over the binding of ligands in cis.